Construction of the Sophia Observation withdrawal Symptoms-scale (SOS) for critically ill children

Abstract

OBJECTIVE: To construct a reliable and clinically practical instrument for monitoring opioids and benzodiazepine withdrawal symptoms in pediatric ICU patients. DESIGN: Instrument development. SETTING: Intensive care unit in an academic children's hospital. PATIENTS AND PARTICIPANTS: 79 patients up to age 16 years on intravenous midazolam and/or opioids for > or =5 days. An expert panel of 85 physicians and nurses rated clinical relevance of withdrawal symptoms. INTERVENTION: During drug weaning repeated observations were performed with a checklist of 24 withdrawal symptoms described in the literature. MEASUREMENTS AND RESULTS: For 76 children, 932 observations were obtained within 24 h after decrease and/or discontinuation of midazolam or opioids. Most frequent symptoms were tachypnea, agitation, motor disturbance, diarrhea, fever, anxiety, sleep disturbance and hypertension (14.6-29.6%). Multidimensional scaling (MDS) was performed to detect the underlying empirical structure of co-occurrences of symptoms. An expert panel judged clinical relevance of each withdrawal symptom on a four-point scale ranging from 'definitively so' to 'definitively not'. Agitation, anxiety, inconsolable crying, increased muscle tension, tremors, tachycardia and sweating were considered relevant by 85-95% of the experts. On the basis of the MDS results and the experts' opinions, 15 symptoms were included in the final instrument. CONCLUSIONS: We are the first to develop an assessment tool for withdrawal symptoms in pediatric ICU patients on the basis of the underlying empirical structure of co-occurrences of withdrawal symptoms that experts considered relevant. Future studies need to define cut-off points and clarify psychometric issues.